ClinicalTrials.gg
Active, not recruitingNCT02817633Updated Oct 28, 2025

A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)

A Phase 1 interventional study of TSR-022 and Nivolumab in Neoplasms, sponsored by Tesaro, Inc.. Active, not recruiting at 89 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-10-28.

Sponsored by Tesaro, Inc. (part of GlaxoSmithKline) · Phase 1, Interventional, and Treatment

How we know · 21 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
463
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a first-in-human study evaluating the anti-T cell immunoglobulin and mucin containing protein-3 (TIM-3) antibody TSR-022. The study will be conducted in 2 parts with Part 1 consisting of dose escalation and Part 2 dose expansion. Part 1 will determine the recommended Phase 2 dose (RP2D) of TSR-022 and Part 2 will evaluate the antitumor activity of TSR-022 in combination with TSR-042 or docetaxel and as monotherapy.

02

Conditions studied

  • Neoplasms

Keywords

  • TSR-022
  • Nivolumab
  • Advanced solid tumors
  • Metastatic solid tumors
  • Immunotherapy
  • Colorectal cancer
  • Non-small cell lung cancer
  • Melanoma
  • TSR-033
  • TSR-042
  • Hepatocellular carcinoma cancer
  • Docetaxel
03

In context

Neoplasms

10,838 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's enrollment of 463 is above the median of 60 across 7,716 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Tesaro, Inc. is the lead sponsor of 33 studies on the registry; none are open to participants now.

Of its 12 completed or terminated interventional studies of FDA-regulated products, 12 (100%) have results posted.

First submitted before Tesaro, Inc. became part of GlaxoSmithKline.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant is at least 18 years of age.
  • Female participants of must have a negative serum or urine pregnancy test within 72 hours prior to the date of the first dose of study medication or be of non-childbearing potential.
  • Participant has an performance status of less than or equal to (\<=)1.
  • Participant has adequate organ function.

Inclusion Criteria for Participants in Part 1 and Part 2 Cohorts A, B, and C:

  • Participant with advanced or solid tumor who meets the requirements for the part of the study/cohort he/she will participate in, as follows:
  • Part 2: proven advanced (unresectable) or metastatic solid tumor that is measurable by computed tomography (CT) or magnetic resonance imaging (MRI) per version 1.1 criteria Inclusion Criteria for Participants in Part 2 Cohort D
  • Participants with advanced or metastatic non-small cell lung carcinoma (NSCLC) that is measurable by CT or MRI per RECIST version 1.1 criteria and meet the following criteria:
  • NSCLC histology includes squamous or non-squamous cell carcinoma.
  • Participants have received no more than 2 , which must include a platinum-based chemotherapy (for example [e.g.], cisplatin, carboplatin) and an anti- programmed death-ligand 1 () antibody.
  • Participants must have documented radiographic progression by RECIST version 1.1 criteria on prior anti-programmed cell death protein (PD-1) or anti-PD-L1 therapy.
  • -All participants enrolled must undergo a biopsy prior to study entry, and the biopsy tissue must be submitted to the central laboratory for all participants in order to determine T-cell immunoglobulin and mucin-domain containing-3 (TIM-3) expression level prior to first dose. If a participant has had a biopsy prior to entering the 35-day screening period and within approximately 12 weeks of study treatment, that biopsy may be accepted as the Baseline fresh biopsy.

Inclusion Criteria for Participants in Part 2 Cohort E

  • Participant is greater than or equal to (>=)18 years old, is able to understand the study procedures, and agrees to participate in the study by providing written which includes compliance with the requirements and restrictions listed in the Informed consent form (ICF) and protocol.
  • Participant has histologically or cytologically proven advanced or metastatic NSCLC, and only squamous or non-squamous cell carcinoma.
  • Participant has received no more than 2 prior lines of therapy for advanced or metastatic disease, which must only include a platinum-based (eg, cisplatin, carboplatin) doublet chemotherapy regimen and an anti-PD-1 or anti-PD-L1 antibody (no other biologic agents alone or in combination; novel combinations are not allowed). Participants previously treated with targeted therapies, including angiogenesis inhibitors (eg, bevacizumab, ramucirumab, lenvatinib), are not eligible.
  • Participant has , that is, presenting with at least 1 measurable lesion per RECIST v1.1 as determined by the local site Investigator/radiology assessment. Target lesions situated in a previously irradiated area are considered measurable if disease progression has been demonstrated in such lesions and if there are other target lesions. If there is only 1 target lesion that was previously irradiated, the participant is not eligible.
  • Participant has documented radiological disease progression on prior platinum-based chemotherapy and on prior anti-PD-1 or anti-PD-L1 therapy according to RECIST v1.1.
  • Participant agrees to submit an archival formalin fixed paraffin embedded (FFPE) tumor tissue specimen that was collected on or after diagnosis of metastatic disease from location(s) not irradiated prior to biopsy. Both tissue block and freshly cut slides are acceptable. If archival tissue is not available, the participant must undergo biopsy prior to study entry.
  • Participant has an ECOG performance status score of 0 or 1.
  • Participant has a of at least 3 months and is anticipated to be able to complete 4 cycles of docetaxel treatment.
  • Participant has adequate organ function as defined in the protocol
  • use by male and female participants should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.

Inclusion Criteria for Participants in Part 2 Cohort F

  • Histologically confirmed locally advanced or metastatic and/or unresectable Hepatocellcular Carcinoma (HCC)

    • Barcelona Clinic Liver Cancer Stage B or C
    • Cirrhosis grade of Class A
  • No prior systemic therapy for HCC
  • Documented testing at screening, including hepatitis B surface antigen (HBsAg), hepatitis B surface antibody (HBsAB) and hepatitis B core antibody (HBcAb). Participants with a positive HBsAg will require negative hepatitis B virus (HBV) DNA testing at screening.

    • Participants with chronic HBV infection (HBsAg +) are required to be receiving effective antiviral therapy (i.e., with Tenofovir or Entecavir) for at least 14 days with willingness to continue for the length of the study and have HBV deoxyribonucleic acid (DNA) less than 100 International Units Per Milliliter (IU/mL) within 28 days prior to initiation of study treatment.
    • Participants with chronic HBV infection (HBsAg+) require documented Hepatitis D virus (HDV) antibody testing conducted at screening. If HDV antibody is positive, then HDV ribonucleic acid (RNA) must be negative to participate.
    • Participants with a negative HBsAg and positive HBcAb result are eligible only if HBV DNA is negative (Past HBV participants).
  • Documented virus (HCV) antibody testing conducted at screening. If HCV antibody is positive, then HCV RNA must be negative. Participants with recently treated HCV prior to study start must be greater than (>)12 weeks from final HCV treatment.
  • Must have measurable disease, defined as at least one tumor lesion that can be accurately measured according to RECIST v1.1
  • Participant agrees to submit an archival FFPE tumor tissue specimen that was collected on or after diagnosis of metastatic disease from location(s) not irradiated prior to biopsy. Both tissue block and freshly cut slides are acceptable. If archival tissue is not available, the participant must undergo biopsy prior to study entry.

    • Participants are also encouraged, but not required, to have a fresh tumor tissue biopsy of a primary or metastatic tumor prior to dosing (samples will be used to enable biomarker analysis).
  • (INR) or prothrombin time (PT) \<= 2× (ULN) unless participant is receiving anticoagulant therapy as long as PT or partial thromboplastin (PTT) is within therapeutic range of intended use of anticoagulants. Activated partial thromboplastin time (aPTT) \<=2×ULN unless participant is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants
  • Negative (HIV) test at screening The Investigator is responsible for review of medical history, menstrual history, and recent sexual activity to decrease the risk for inclusion of a woman with an early undetected pregnancy.

Exclusion criteria

Exclusion criteria:

  • History of Grade greater than or equal to (>=)3 immune-related AE with prior immunotherapy, with the exception of non- lab abnormalities.
  • Participant has known uncontrolled central nervous system (CNS) and/or carcinomatous meningitis.
  • Participant has a known additional that progressed or required active treatment within the last 2 years. Participants with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the regimen may be included only after discussion with the Medical Monitor.
  • Participant is considered a poor medical risk due to a serious, uncontrolled medical disorder, non-malignant systemic disease or active infection requiring systemic therapy.
  • Participant is pregnant or breastfeeding or expecting to conceive children within the projected duration of the study, starting with the Screening Visit through 150 days after the last dose of study treatment.
  • Participant has a diagnosis of immunodeficiency or is receiving systemic therapy or any other form of therapy within 7 days prior to the first dose of study treatment.

Exclusion Criteria for Participants in Part 2 Cohort D

  • A participant with negative (as determined by Central Testing Lab) or unevaluable TIM-3 expression from tissue obtained prior to study entry will not be eligible for the study.
  • Participant has received prior therapy as defined below:
  • Prior treatment with , anti-PD-L1, or anti-PD-L2 agent that resulted in permanent discontinuation due to an AE.
  • Prior treatment with an anti-lymphocyte activation gene (LAG)-3 or anti-TIM-3.
  • Radiologic or clinical progression \<= 8 weeks after initiation of prior anti-PD-1 or anti-PD-L1 antibody.
  • Participants with known epidermal growth factor receptor (EGFR) mutation, anaplastic lymphoma kinase (ALK) translocation, or receptor tyrosine kinase (ROS1) mutation.
  • Participant has received a vaccine other than a vaccine against severe acute respiratory syndrome (SARS)-coronavirus 2 (CoV-2) infection ("Coronavirus Disease 2019" [COVID-19]) within 7 days of planned start of study therapy. The use of all COVID-19 vaccines is allowed, with the exception of COVID-19 vaccines using the recombinant adenoviral vector platform within 30 days of planned start of study therapy. If a COVID-19 vaccine using this platform is to be administered within 30 days of planned start of study therapy, this must first be discussed with and approved by the Sponsor's Medical Monitor.

Exclusion Criteria for Participants in Part 2 Cohort E

  • Participant has been previously treated with an anti PD 1, anti PD L1, or anti PD L2 agent that resulted in permanent discontinuation due to an AE
  • Participant has been previously treated with an anti TIM-3 or anti cytotoxic T lymphocyte-associated protein 4 (CTLA 4) agent or docetaxel.
  • Participant has a documented sensitizing EGFR, ALK, or ROS-1 mutation. Participants whose tumors have not been tested for these driver mutations and therefore who have unknown driver mutation status are not eligible. Participants with squamous histology do not need to be tested for these driver mutations.
  • Participant had radiological or clinical disease progression (that is [ie,] worsening performance status, clinical symptoms, and laboratory data) \<=8 weeks after initiation of prior anti PD 1 or anti-PD-L1 antibody. The clinical disease progression should have been confirmed by a subsequent radiological scan.
  • Participant has received radiation to the lung that is >30 Gray (Gy) within 6 months prior to the first dose of study treatment.
  • Participant has completed palliative radiotherapy within 7 days prior to the first dose of study treatment.
  • Participant has an additional malignancy or a history of prior malignancy, with the exception of adequately treated basal or squamous skin cancer, cervical carcinoma in situ, or bladder carcinoma in situ without evidence of disease, or had a malignancy treated with curative intent and with no evidence of disease recurrence for 5 years since the initiation of that therapy.
  • Participant has known new or progressive and/or . Participants who have received prior therapy for their brain metastases and have radiologically stable central nervous system disease may participate, provided they are neurologically stable for at least 4 weeks before study entry and are off corticosteroids within 3 days prior to the first dose of study treatment.
  • Participant has tested positive for the following at Screening or within 3 months before the first dose of study treatment:
  • Presence of surface antigen.
  • Presence of antibody in the absence of an Ribonucleic acid (RNA) test for hepatitis C virus.
  • Participant has known (HIV) (positive for HIV 1 or HIV 2 antibodies).
  • Participant has active disease that required systemic treatment in the past 2 years, is immunocompromised in the opinion of the Investigator, or is receiving systemic immunosuppressive treatment. Replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid replacement therapy of prednisone, or equivalent, for adrenal or pituitary insufficiency) is not considered a form of systemic treatment.
  • Participant has received systemic steroid therapy within 3 days prior to the first dose of the study treatment or is receiving any other form of immunosuppressive medication. Replacement therapy is not considered a form of systemic therapy. Use of inhaled corticosteroids, local steroid injection, or steroid eye drops is allowed.
  • Participant has current interstitial lung disease, current pneumonitis, or a history of pneumonitis that required the use of glucocorticoids to assist with management. Lymphangitic spread of the NSCLC is not exclusionary.
  • Participant does not meet requirements per local prescribing guidelines for receiving treatment with docetaxel, including severe reactions to drugs formulated with polysorbate 80.
  • Participant has received prior anticancer therapy (chemotherapy, targeted therapies, radiotherapy, or immunotherapy) within 21 days, or less than 5 times the half life of the most recent therapy prior to study Day 1, whichever is shorter.

Exclusion Criteria for Participants in Part 2 Cohort F

  • Known fibrolamellar HCC, sarcomatoid HCC or mixed cholangiocarcinoma and HCC
  • Participant must not have had major surgery \<= 3 weeks prior to initiating protocol therapy and participant must have recovered from any surgical effects
  • Participants must not have received investigational therapy \<= 4 weeks, or within a time interval less than at least 5 half-lives of the investigational agent, whichever is shorter, prior to initiating protocol therapy.
  • Active or untreated central nervous system (CNS) and leptomeningeal metastases
  • Prior therapy with any medication targeting PD-1, PD-L1, or TIM-3
  • Participant must not have a known hypersensitivity to TSR-042 and TSR-022 components or .
  • Participants with active malignancy (other than HCC) or a prior malignancy within the past 2 years are excluded. Participants with completely resected cutaneous melanoma (early stage), basal cell carcinoma, cutaneous squamous cell carcinoma, cervical carcinoma in-situ, breast carcinoma in-situ, and localized prostate cancer are eligible
  • Participant must not have serious, uncontrolled medical disorder, or nonmalignant systemic disease as determined by the treating physician. Examples include, but are not limited to uncontrolled ventricular arrhythmia, uncontrolled major seizure disorder, unstable spinal cord compression, or superior vena cava syndrome.
  • Has a history or evidence of cardiac abnormalities within the 6 months prior to enrollment, including:

    • Serious, uncontrolled cardiac arrhythmia or clinically significant abnormalities including second-degree (Type II) or third-degree atrioventricular (AV) block.
    • Cardiomyopathy, myocarditis, myocardial infarction, acute coronary syndromes (including angina pectoris), coronary angioplasty, stenting, or bypass grafting.
    • Congestive heart failure [ (NYHA) Class III or IV]
    • Symptomatic pericarditis
  • Known history of HIV infection
  • Active tuberculosis infection or other microbial infection or any active systemic infection requiring parenteral antibiotic therapy. All prior infections must have resolved following optimal therapy.
  • Participant has an active autoimmune disease that has required systemic treatment in the past 2 years (. i.e., with use of disease-modifying agents, corticosteroids, or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.
  • History of idiopathic pulmonary fibrosis, interstitial lung disease, bronchial asthma, organizing pneumonia, bronchiolitis obliterans, drug-induced pneumonitis, or idiopathic pneumonitis
  • History of organ transplantation including bone marrow transplantation
  • Participant has a diagnosis of immunodeficiency or has been receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to initiating protocol therapy.
  • Participant has received a within 7 days of initiating protocol therapy. Seasonal flu vaccines that do not contain live virus and COVID 19 vaccines are permitted.
  • Psychiatric illness/social situations that would limit compliance with study requirements
  • Pregnant, lactating, breastfeeding, or intending to become pregnant during the study and for 150 days after the study
Terms in these criteria, in plain language(32)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
463 participants (actual)

Study arms

  • Experimental
    Part 1a: TSR-022 monotherapy

    Drug: TSR-022

  • Experimental
    Part 1b: TSR-022 in combination with nivolumab

    Drug: TSR-022 · Drug: Nivolumab

  • Experimental
    Part 1c: TSR-022 in combination with TSR-042

    Drug: TSR-022 · Drug: TSR-042

  • Experimental
    Part 1d: TSR-022 in combination with TSR-042 and TSR-033

    Drug: TSR-022 · Drug: TSR-042 · Drug: TSR-033

  • Experimental
    Part 1e: TSR-022 with TSR-042 (not previously treated with anti-programmed death ligand [PD-{L}]1)

    Drug: TSR-022 · Drug: TSR-042

  • Experimental
    Part 1f: TSR-022 in combination with TSR-042 and Docetaxel

    Drug: TSR-022 · Drug: TSR-042 · Drug: Docetaxel

  • Experimental
    Part 1g: TSR-022 in combination with TSR-042, pemetrexed, and cisplatin

    Drug: TSR-022 · Drug: TSR-042 · Drug: Pemetrexed · Drug: Cisplatin

  • Experimental
    Part 1h: TSR-022 in combination with TSR-042, pemetrexed, and carboplatin

    Drug: TSR-022 · Drug: TSR-042 · Drug: Pemetrexed · Drug: Carboplatin

  • Experimental
    Part 2: Cohort A Melanoma-TSR-022 as monotherapy

    Drug: TSR-022

  • Experimental
    Part 2: Cohort A Melanoma-TSR-022 with TSR-042

    Drug: TSR-022 · Drug: TSR-042

  • Experimental
    Part 2:Cohort B Non-small cell lung cancer-TSR-022-monotherapy

    Drug: TSR-022

  • Experimental
    Part 2:Cohort B Non-small cell lung cancer-TSR-022 with TSR-042

    Drug: TSR-022 · Drug: TSR-042

  • Experimental
    Part 2:Cohort C Colorectal cancer-TSR-022 as monotherapy

    Drug: TSR-022

  • Experimental
    Part 2:Cohort C Colorectal cancer-TSR-022 with TSR-042

    Drug: TSR-022 · Drug: TSR-042

  • Experimental
    Part 2: Cohort D-TIM-3 selected non-small cell lung cancer (NSCLC)-TSR-022 with TSR-042

    Drug: TSR-022 · Drug: TSR-042

  • Experimental
    Part 2: Cohort E-Non-small cell lung cancer-TSR-022 with docetaxel

    Drug: TSR-022 · Drug: Docetaxel

  • Experimental
    Part 2: Cohort F- Hepatocellular carcinoma (HCC)-TSR-022 with TSR-042

    Drug: TSR-022 · Drug: TSR-042

Interventions

06

What researchers measure

Primary outcomes

  1. Part 1 (a): Number of participants achieving dose limiting toxicity (DLTs)

    Time frame: Up to 28 days

  2. Part 1 (b,c,d): Number of participants achieving dose limiting toxicity (DLTs)

    Time frame: Up to 42 days

  3. Part 1 (f,g,h): Number of participants achieving dose limiting toxicity (DLTs)

    Time frame: Up to 21 days

  4. Part 1: Number of participants with adverse events (AEs), serious adverse events (SAEs), AEs leading to discontinuation, treatment emergent adverse events (TEAEs), TEAEs leading to death and immune-related adverse events (irAEs)

    Time frame: Up to 2 years

  5. Part 1: Number of participants with clinically significant changes in laboratory parameters, vital signs, electrocardiogram (ECG) findings, Eastern Cooperative Oncology Group (ECOG) status, physical examination and use of concomitant medications

    Time frame: Up to 2 years

  6. Part 1 (e) and Part 2: Overall Response Rate (ORR) by Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1

    Time frame: Up to 2 years

Secondary outcomes

  1. Part 1 (a, b, c, d, f, g, h): ORR by RECIST v 1.1

    Time frame: Up to 2 years

  2. Part 2 (A, B, C, D): ORR by Immune related RECIST (irRECIST)

    Time frame: Up to 2 years

  3. Part 2: Duration of response (DOR) by RECIST v 1.1

    Time frame: Up to 2 years

  4. Part 2 (A, B, C, D): DOR by irRECIST

    Time frame: Up to 2 years

  5. Parts 1 and 2: Disease control rate (DCR) by RECIST v 1.1

    Time frame: Up to 2 years

  6. Part 2 (A, B, C, D): DCR by irRECIST

    Time frame: Up to 2 years

  7. Part 2: Progression-free survival (PFS) by RECIST v 1.1

    Time frame: Up to 2 years

  8. Part 2 (A, B, C, D): PFS by irRECIST

    Time frame: Up to 2 years

  9. Parts 1 and 2 (A, B, C, D, E, F): Serum concentration of TSR-022

    Time frame: Up to 2 years

  10. Part 1d: Serum concentration of TSR-033

    Time frame: Up to 2 years

  11. Part 1 (c, d, e, f, g, h): Serum concentration of TSR-042

    Time frame: Up to 2 years

  12. Part 2 (A, B, C, D, F): Serum concentration of TSR-042

    Time frame: Up to 2 years

  13. Part 2: Overall survival (OS)

    Time frame: Up to 2 years

  14. Part 1a: Minimum plasma concentration (Cmin) of TSR-022 as monotherapy

    Time frame: Up to 2 years

  15. Part 1b: Cmin of TSR-022 in combination with nivolumab

    Time frame: Up to 2 years

  16. Part 1c: Cmin of TSR-022 in combination with TSR-042

    Time frame: Up to 2 years

  17. Part 1d: Cmin of TSR-022 in combination with TSR-042 and TSR-033

    Time frame: Up to 2 years

  18. Part 2F: Cmin of TSR-022 in combination with TSR-042

    Time frame: Up to 2 years

  19. Part 1a: Area under the concentration × time curve from time 0 to infinity AUC (0-inf) of TSR-022 as monotherapy

    Time frame: Up to 2 years

  20. Part 1b: AUC (0-inf) of TSR-022 in combination with nivolumab

    Time frame: Up to 2 years

  21. Part 1c: AUC (0-inf) of TSR-022 in combination with TSR-042

    Time frame: Up to 2 years

  22. Part 1d: AUC (0-inf) of TSR-022 in combination with TSR-042 and TSR-033

    Time frame: Up to 2 years

  23. Part 2F: AUC (0-inf) of TSR-022 in combination with TSR-042

    Time frame: Up to 2 years

  24. Part 1a: Area under the concentration time curve from time 0 to last assessment (AUC 0-last) of TSR-022 as monotherapy

    Time frame: Up to 2 years

  25. Part 1b: AUC (0-last) of TSR-022 in combination with nivolumab

    Time frame: Up to 2 years

  26. Part 1c: AUC (0-last) of TSR-022 in combination with TSR-042

    Time frame: Up to 2 years

  27. Part 1d: AUC (0-last) of TSR-022 in combination with TSR-042 and TSR-033

    Time frame: Up to 2 years

  28. Part 2F: AUC (0-last) of TSR-022 in combination with TSR-042

    Time frame: Up to 2 years

  29. Part 1a: Terminal half life (t 1/2) of TSR-022 as monotherapy

    Time frame: Up to 2 years

  30. Part 1b: t1/2 of TSR-022 and in combination with nivolumab

    Time frame: Up to 2 years

  31. Part 1c: t1/2 of TSR-022 in combination with TSR-042

    Time frame: Up to 2 years

  32. Part 1d: t1/2 of TSR-022 in combination with TSR-042 and TSR-033

    Time frame: Up to 2 years

  33. Part 2F: t1/2 of TSR-022 in combination with TSR-042

    Time frame: Up to 2 years

  34. Part 1a: Area under the concentration × time curve during the dosing interval (AUCtau) of TSR-022 as monotherapy

    Time frame: Up to 2 years

  35. Part 1b: AUCtau of TSR-022 and in combination with nivolumab

    Time frame: Up to 2 years

  36. Part 1c: AUCtau of TSR-022 in combination with TSR-042

    Time frame: Up to 2 years

  37. Part 1d: AUCtau of TSR-022 in combination with TSR-042 and TSR-033

    Time frame: Up to 2 years

  38. Part 2F: AUCtau of TSR-022 in combination with TSR-042

    Time frame: Up to 2 years

  39. Part 1: Number of participants with anti-drug antibodies (ADAs) to TSR-022

    Time frame: Up to 2 years

  40. Part 2 (A, B, C, D, E, F): Number of participants with ADA to anti-TSR-022

    Time frame: Up to 2 years

  41. Part 1 (c, d, e, f, g, h): Number of participants with ADA to TSR-042

    Time frame: Up to 2 years

  42. Part 2 (A, B, C, D, F): Number of Participants with ADA to TSR-042

    Time frame: Up to 2 years

  43. Part 1d: Number of participants with ADA to TSR-033

    Time frame: Up to 2 years

  44. Part 2F: Number of participants with AEs, SAEs, AEs leading to discontinuation, TEAEs, TEAEs leading to death

    Time frame: Up to 2 years

  45. Part 2F: Percent change from Baseline in Alpha-fetoprotein (AFP)

    Time frame: Baseline, and up to 2 years

07

Study locations

89 sites
  • GSK Investigational Site
    Goodyear, Arizona 85338, United States
  • GSK Investigational Site
    Scottsdale, Arizona 85258, United States
  • GSK Investigational Site
    Tucson, Arizona 85704, United States
  • GSK Investigational Site
    Tucson, Arizona 85711, United States
  • GSK Investigational Site
    Encinitas, California 92024, United States
  • GSK Investigational Site
    Fountain Valley, California 92708, United States
  • GSK Investigational Site
    Los Angeles, California 90024, United States
  • GSK Investigational Site
    Los Angeles, California 90025, United States
  • GSK Investigational Site
    San Marcos, California 92069, United States
  • GSK Investigational Site
    Whittier, California 90606, United States
  • GSK Investigational Site
    Aurora, Colorado 80012, United States
  • GSK Investigational Site
    Aurora, Colorado 80045, United States
  • GSK Investigational Site
    Denver, Colorado 80218, United States
  • GSK Investigational Site
    New Haven, Connecticut 06511, United States
  • GSK Investigational Site
    Washington D.C., District of Columbia 20007, United States
  • GSK Investigational Site
    Jacksonville, Florida 32224, United States
  • GSK Investigational Site
    Miami, Florida 33140, United States
  • GSK Investigational Site
    Sarasota, Florida 34232, United States
  • GSK Investigational Site
    Tampa, Florida 33612, United States
  • GSK Investigational Site
    Atlanta, Georgia 30322, United States
  • GSK Investigational Site
    Augusta, Georgia 30912, United States
  • GSK Investigational Site
    Arlington Heights, Illinois 60005, United States
  • GSK Investigational Site
    Chicago, Illinois 60637, United States
  • GSK Investigational Site
    Niles, Illinois 60714, United States
  • GSK Investigational Site
    Iowa City, Iowa 52242, United States
  • GSK Investigational Site
    Wichita, Kansas 67214, United States
  • GSK Investigational Site
    Louisville, Kentucky 40202, United States
  • GSK Investigational Site
    Pikeville, Kentucky 41501, United States
  • GSK Investigational Site
    Wheaton, Maryland 20850, United States
  • GSK Investigational Site
    Boston, Massachusetts 02114, United States
  • GSK Investigational Site
    Detroit, Michigan 48202, United States
  • GSK Investigational Site
    Rochester, Minnesota 55905, United States
  • GSK Investigational Site
    Florissant, Missouri 63031, United States
  • GSK Investigational Site
    St Louis, Missouri 63110, United States
  • GSK Investigational Site
    St Louis, Missouri 63129, United States
  • GSK Investigational Site
    St Louis, Missouri 63141, United States
  • GSK Investigational Site
    Hackensack, New Jersey 07601, United States
  • GSK Investigational Site
    New York, New York 10016, United States
  • GSK Investigational Site
    The Bronx, New York 10461, United States
  • GSK Investigational Site
    Cincinnati, Ohio 45242, United States
  • GSK Investigational Site
    Cleveland, Ohio 44106, United States
  • GSK Investigational Site
    Toledo, Ohio 43623, United States
  • GSK Investigational Site
    Eugene, Oregon 97401, United States
  • GSK Investigational Site
    Vancouver, Oregon 97213-2982, United States
  • GSK Investigational Site
    Bethlehem, Pennsylvania 18015, United States
  • GSK Investigational Site
    Pittsburgh, Pennsylvania 15232, United States
  • GSK Investigational Site
    Charleston, South Carolina 29425, United States
  • GSK Investigational Site
    Greenville, South Carolina 29605, United States
  • GSK Investigational Site
    Nashville, Tennessee 37203, United States
  • GSK Investigational Site
    Austin, Texas 78705, United States
  • GSK Investigational Site
    Dallas, Texas 75246, United States
  • GSK Investigational Site
    Fort Worth, Texas 76104, United States
  • GSK Investigational Site
    Houston, Texas 77030, United States
  • GSK Investigational Site
    Longview, Texas 75601, United States
  • GSK Investigational Site
    McAllen, Texas 78503-1298, United States
  • GSK Investigational Site
    San Antonio, Texas 78229, United States
  • GSK Investigational Site
    Temple, Texas 76508, United States
  • GSK Investigational Site
    Tyler, Texas 75702, United States
  • GSK Investigational Site
    Fairfax, Virginia 22031, United States
  • GSK Investigational Site
    Kennewick, Washington 99336, United States
  • GSK Investigational Site
    Puyallup, Washington 98373, United States
  • GSK Investigational Site
    Seattle, Washington 98111, United States
  • GSK Investigational Site
    Tacoma, Washington 98405, United States
  • GSK Investigational Site
    Madison, Wisconsin 53792, United States
  • GSK Investigational Site
    Daegu, 42601, South Korea
  • GSK Investigational Site
    Seoul, 02841, South Korea
  • GSK Investigational Site
    Seoul, 03722, South Korea
  • GSK Investigational Site
    Seoul, 06351, South Korea
  • GSK Investigational Site
    Seoul, 7061, South Korea
  • GSK Investigational Site
    Barcelona, 08017, Spain
  • GSK Investigational Site
    Barcelona, 08025, Spain
  • GSK Investigational Site
    Barcelona, 8035, Spain
  • GSK Investigational Site
    Girona, 17007, Spain
  • GSK Investigational Site
    Jerez de la Frontera, 11407, Spain
  • GSK Investigational Site
    L'Hospitalet de Llobrega, 08908, Spain
  • GSK Investigational Site
    Las Palmas de Gran Canar, 35016, Spain
  • GSK Investigational Site
    Madrid, 28027, Spain
  • GSK Investigational Site
    Madrid, 28040, Spain
  • GSK Investigational Site
    Madrid, 28041, Spain
  • GSK Investigational Site
    Madrid, 28046, Spain
  • GSK Investigational Site
    Madrid, 28222, Spain
  • GSK Investigational Site
    Málaga, 29010, Spain
  • GSK Investigational Site
    Palma de Mallorca, 07120, Spain
  • GSK Investigational Site
    Pamplona, 31008, Spain
  • GSK Investigational Site
    Santander, 39008, Spain
  • GSK Investigational Site
    Seville, 41013, Spain
  • GSK Investigational Site
    Valencia, 46010, Spain
  • GSK Investigational Site
    Valencia, 46026, Spain
  • GSK Investigational Site
    Zaragoza, 50009, Spain
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2016 (actual). Primary completion is estimated for Mar 2027, 127 months after the start.

Of 676 industry-sponsored phase 1 interventional studies under Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 61. This study's planned 127 months is above that.

Counting every sponsor, half of 903 studies reached it within 40 months; a quarter within 23 and three quarters within 64.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 22, 2016
First posted
Jun 29, 2016
StartActual
Jul 8, 2016
Primary completionEst.
Mar 1, 2027
CompletionEst.
Mar 1, 2027
Last update
Oct 28, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 28, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02817633
Lead sponsor
Tesaro, Inc.
Responsible party
Sponsor
First posted
Jun 29, 2016
Start date
Jul 8, 2016
Primary completion
Mar 1, 2027 (estimated)
Completion
Mar 1, 2027 (estimated)
Last update
Oct 28, 2025

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cobolimab

Start the discussion